News headlines about NuVasive (NASDAQ:NUVA) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NuVasive earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the medical device company an impact score of 46.8446180547279 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- NuVasive, Inc. (NUVA) Expected to Post Quarterly Sales of $260.59 Million (americanbankingnews.com)
- Bone Grafts Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023 (openpr.com)
- Financial Survey: NuVasive (NUVA) versus Cryolife (CRY) (americanbankingnews.com)
- Gregory T. Lucier Purchases 6,000 Shares of NuVasive, Inc. (NUVA) Stock (americanbankingnews.com)
- John A. DeFord, Ph.D. Joins NuVasive Board (ryortho.com)
Shares of NuVasive (NUVA) opened at $50.74 on Wednesday. The stock has a market cap of $2,596.66, a price-to-earnings ratio of 26.39, a P/E/G ratio of 1.30 and a beta of 0.50. NuVasive has a 12 month low of $44.62 and a 12 month high of $81.68. The company has a quick ratio of 1.94, a current ratio of 3.48 and a debt-to-equity ratio of 0.73.
A number of equities research analysts have commented on NUVA shares. Needham & Company LLC raised shares of NuVasive from an “underperform” rating to a “buy” rating and set a $71.00 price objective on the stock in a research report on Thursday, January 4th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $90.00 target price on shares of NuVasive in a research report on Tuesday, January 9th. BidaskClub upgraded shares of NuVasive from a “strong sell” rating to a “sell” rating in a research note on Friday, March 2nd. Morgan Stanley restated an “equal weight” rating and issued a $55.00 target price (down previously from $67.00) on shares of NuVasive in a research note on Tuesday, February 27th. Finally, BMO Capital Markets restated a “buy” rating and issued a $70.00 target price on shares of NuVasive in a research note on Thursday, December 14th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $68.19.
In other news, CEO Gregory T. Lucier acquired 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 6th. The shares were purchased at an average price of $50.30 per share, for a total transaction of $301,800.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.20% of the company’s stock.
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.